Pricing Log in Create free account

Iovance Biotherapeutics, Inc. (IOVA) vs Parabilis Medicines, Inc. (PBLS)

Iovance Biotherapeutics, Inc. and Parabilis Medicines, Inc. are both Biotechnology companies. Iovance Biotherapeutics, Inc. and Parabilis Medicines, Inc. are of similar size ($3.5B and $3.4B). Parabilis Medicines, Inc. has the higher net margin (0.00% vs −58.2%) and the higher return on invested capital (0.00% vs −17.7%). Across the 13 metrics below, Parabilis Medicines, Inc. leads on 9 and Iovance Biotherapeutics, Inc. on 4.

Valuation

Metric IOVA PBLS Biotechnology median
P/E n/m n/m 10.26
P/S 9.29 n/m 9.18
P/B 4.33 0.77 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m 1.79 0.65
EV/Sales 8.51 n/m 8.98
Earnings yield (6.78%) (297.78%) (34.89%)
Free cash flow yield (6.14%) (14.78%) (24.52%)

Profitability

Metric IOVA PBLS Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin (60.79%) 0.00% 0.00%
Net margin (58.19%) 0.00% 0.00%
Free cash flow margin (57.01%) 0.00% 0.00%
Return on equity (29.11%) 0.00% (50.12%)
Return on assets (23.26%) 0.00% (45.60%)
Return on invested capital (17.72%) 0.00% 0.00%

Growth

Metric IOVA PBLS Biotechnology median
Revenue growth (TTM) 51.34% — 6.26%
EPS growth (last fiscal year) 14.84% (10.69%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric IOVA PBLS Biotechnology median
Debt to equity 0.00 0.01 0.00
Current ratio 5.20 17.91 4.89
Net debt to EBITDA 0.82 0.09 1.01

Dividend

Metric IOVA PBLS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IOVA PBLS Biotechnology median
Market cap 3.51b 3.44b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack